On 13.03.2019, the SAMR (State Administration for Market Regulation) released new review measures for advertisements for pharmaceuticals, medical devices, health foods, and food for special medical purpose. The draft is open to public comments.
On 22.03.2019, the NMPA (National Medical Products Administration – former CFDA) released an announcement on 9 cosmetics test methods (NMPA No. 2019-12), which will be relevant for cosmetics registration, filing, and supervision and inspection starting January 1, 2020. Five testing methods of the “Cosmetic Safety Technical Specification (2015 edition)” were revised and four were added.
Stefan Fischer is a trusted partner of Advantage Austria, Foreign Trade Center of the Austrian Federal Economic Chamber. For export to China or local production for the Chinese market, depending on the product, certain certifications or approvals may be made, such as: China Compulsory Certification (CCC) or China Food and Drug Administration (CFDA). The webinar
In the article A fortunate opportunity? Navigating Chinese regulation challenges to ensure success Anna Fischer from Cisema Hong Kong sets out the key challenges that foreign manufacturers of medical devices face in obtaining approval for and access to the Chinese market. Read the article on MedTech ENGINE.
On 14.08.2018, the SAMR defined the 8th batch of Drug – Medical Device Combination Products in their announcement No. 218-2018. When applicants are unsure, whether a product is categorized as a medical device or drug, a classification application can be submitted to the SAMR for verification.
On 26.07.2018, the SAMR has released a draft for public comment on technical guidelines for formula changes of infant formula milk powder. As long as the type of raw materials, the order of ingredients and the table of nutrients remain the same, food raw materials and food additives are allowed to reasonably fluctuate within a
On 01.08.2018, the SDA published the interpretation for the new Medical Device catalogue, which contains some changes regarding classifications. Some Class II products have been upgraded to Class III and some Class III products shall be considered as Class II.
As mentioned in our March/April news: On 13.03.2018, during the 13th National People’s Congress, China’s cabinet decided for the SAMR (State Administration for Market Regulation) to supervise the – CFDA (China Food and Drug Administration), – AQSIQ (General Administration of Quality Supervision, Inspection and Quarantine), and – SAIC (State Administration for Industry and Commerce). The
On 27.09.2018, the CFDA published two Medical Device Regulation Indices (1998-2013) (CFDA WeChat announcement Nr.37. 2018). The first Index includes 114 still valid regulatory documents, covering classifications of specific devices, regulations for non-medical devices, technical guidelines, industry standards, GMPs and post-market penalties. The second Index includes 119 regulatory documents, which are no longer valid.
On 29.09.2018, the CFDA released the “Supervision and Management Regulations of Customised Medical Devices” for public comment. Customized medical devices are personalized products, which meet rare or specific needs of designated patients and are expected to improve the effect of diagnosis and treatment.